These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33960504)

  • 1. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
    Jackson CGCA; Hung T; Segelov E; Barlow P; Prenen H; McLaren B; Hung NA; Clarke K; Chao TY; Dai MS; Yeh HT; Cutler DL; Kramer D; He J; Zhi J; Chan WK; Kwan R; Deva S
    Br J Clin Pharmacol; 2021 Dec; 87(12):4670-4680. PubMed ID: 33960504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
    Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
    Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    Rugo HS; Umanzor GA; Barrios FJ; Vasallo RH; Chivalan MA; Bejarano S; Ramírez JR; Fein L; Kowalyszyn RD; Kramer ED; Wang H; Kwan MR; Cutler DL;
    J Clin Oncol; 2023 Jan; 41(1):65-74. PubMed ID: 35858154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral docetaxel plus encequidar - a phase 1 clinical trial.
    Wang D; Hung N; Hung T; Eden K; Chan WK; Kwan R; Qin A; Chang C; Duffull S; Glue P; Jackson C
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):475-481. PubMed ID: 38814342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
    Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of taxanes.
    Malingré MM; Beijnen JH; Schellens JH
    Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
    Sharma D; Wojtynek J; Fox KM; Cooper C; Dokubo I
    Am J Manag Care; 2021 Feb; 27(2 Spec. No.):SP46-SP50. PubMed ID: 33395244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
    Smolinski MP; Urgaonkar S; Pitzonka L; Cutler M; Lee G; Suh KH; Lau JYN
    J Med Chem; 2021 Apr; 64(7):3677-3693. PubMed ID: 33729781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
    He J; Jackson CGCA; Deva S; Hung T; Clarke K; Segelov E; Chao TY; Dai MS; Yeh HT; Ma WW; Kramer D; Chan WK; Kwan R; Cutler D; Zhi J
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):867-879. PubMed ID: 35470967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and
    Zeng W; Kwan Law BY; Wai Wong VK; Bik Chan DS; Fai Mok SW; Ying Gao JJ; Yan Ho RK; Liang X; Li JH; Lee MT; Yoon WL; Smolinski MP; Nam Lau JY; Kei Lam CW; Fok M
    Cancer Biol Med; 2020 Nov; 17(4):986-1001. PubMed ID: 33299648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
    Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
    Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects.
    Abebe BT; Weiss M; Modess C; Roustom T; Tadken T; Wegner D; Schwantes U; Neumeister C; Schulz HU; Scheuch E; Siegmund W
    J Clin Pharmacol; 2019 Oct; 59(10):1319-1330. PubMed ID: 30973998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
    Yang S; Gursoy RN; Lambert G; Benita S
    Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.
    Woo JS; Lee CH; Shim CK; Hwang SJ
    Pharm Res; 2003 Jan; 20(1):24-30. PubMed ID: 12608532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats.
    Föger F; Malaivijitnond S; Wannaprasert T; Huck C; Bernkop-Schnürch A; Werle M
    J Drug Target; 2008 Feb; 16(2):149-55. PubMed ID: 18274935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
    Callies S; de Alwis DP; Harris A; Vasey P; Beijnen JH; Schellens JH; Burgess M; Aarons L
    Br J Clin Pharmacol; 2003 Jul; 56(1):46-56. PubMed ID: 12848775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers.
    Nardi-Hiebl S; Ndieyira JW; Al Enzi Y; Al Akkad W; Koch T; Geldner G; Reyher C; Eberhart LHJ
    Pain Res Manag; 2021; 2021():2887773. PubMed ID: 34880961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
    van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
    Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
    ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
    Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.